Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157845 · ClinicalTrials.gov registry record · Phase 3
Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
A Phase 3 study of Cirrhosis, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
- 4
- Study locations
NCT01157845 is a Phase 3 study of Cirrhosis that has completed, run by Virginia Commonwealth University. The registered enrollment target is 165 participants, below the 90,406-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01157845, a Phase 3 study of Cirrhosis, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
- 4
- Study locations
Study Summary
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.
Conditions Studied
Interventions
- DEVICE BreathID (Methacetin breath test)
Study Locations (4)
Michigan
- Henry Ford Health System - Detroit
South Carolina
- Medical University of South Carolina - Charleston
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Israel
- Hadassah Medical Center - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01157845
The ClinicalTrials.gov registry entry for NCT01157845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,406-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which BreathID (Methacetin breath test) is the first listed.
NCT01157845 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT01157845 about?
NCT01157845 is a clinical study titled "Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis". The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver functio...
What is the current status of trial NCT01157845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2010-03. Estimated completion is 2012-07.
What conditions does trial NCT01157845 study?
This clinical trial studies the following conditions: Cirrhosis.
What interventions are being tested in trial NCT01157845?
The interventions under investigation include: BreathID (Methacetin breath test) (DEVICE).
Who is sponsoring clinical trial NCT01157845?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01157845 being conducted?
This trial has 4 study locations across Michigan, South Carolina, Virginia, Israel. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
ACTIVE NOT RECRUITING · Phase 3
-
Gabapentin to Treat Itch in Patients With Liver Disease
COMPLETED · Phase 3
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.